These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

318 related items for PubMed ID: 22733064

  • 1. Pan-β-lactam resistance development in Pseudomonas aeruginosa clinical strains: molecular mechanisms, penicillin-binding protein profiles, and binding affinities.
    Moyá B, Beceiro A, Cabot G, Juan C, Zamorano L, Alberti S, Oliver A.
    Antimicrob Agents Chemother; 2012 Sep; 56(9):4771-8. PubMed ID: 22733064
    [Abstract] [Full Text] [Related]

  • 2. Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
    Moya B, Zamorano L, Juan C, Pérez JL, Ge Y, Oliver A.
    Antimicrob Agents Chemother; 2010 Mar; 54(3):1213-7. PubMed ID: 20086158
    [Abstract] [Full Text] [Related]

  • 3. Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
    Castanheira M, Mills JC, Farrell DJ, Jones RN.
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6844-50. PubMed ID: 25182652
    [Abstract] [Full Text] [Related]

  • 4. Affinity of the new cephalosporin CXA-101 to penicillin-binding proteins of Pseudomonas aeruginosa.
    Moyá B, Zamorano L, Juan C, Ge Y, Oliver A.
    Antimicrob Agents Chemother; 2010 Sep; 54(9):3933-7. PubMed ID: 20547785
    [Abstract] [Full Text] [Related]

  • 5. PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability.
    Montaner M, Lopez-Argüello S, Oliver A, Moya B.
    Microbiol Spectr; 2023 Feb 14; 11(1):e0303822. PubMed ID: 36475840
    [Abstract] [Full Text] [Related]

  • 6. Overexpression of AmpC and efflux pumps in Pseudomonas aeruginosa isolates from bloodstream infections: prevalence and impact on resistance in a Spanish multicenter study.
    Cabot G, Ocampo-Sosa AA, Tubau F, Macia MD, Rodríguez C, Moya B, Zamorano L, Suárez C, Peña C, Martínez-Martínez L, Oliver A, Spanish Network for Research in Infectious Diseases (REIPI).
    Antimicrob Agents Chemother; 2011 May 14; 55(5):1906-11. PubMed ID: 21357294
    [Abstract] [Full Text] [Related]

  • 7. Genomics and Susceptibility Profiles of Extensively Drug-Resistant Pseudomonas aeruginosa Isolates from Spain.
    Del Barrio-Tofiño E, López-Causapé C, Cabot G, Rivera A, Benito N, Segura C, Montero MM, Sorlí L, Tubau F, Gómez-Zorrilla S, Tormo N, Durá-Navarro R, Viedma E, Resino-Foz E, Fernández-Martínez M, González-Rico C, Alejo-Cancho I, Martínez JA, Labayru-Echverria C, Dueñas C, Ayestarán I, Zamorano L, Martinez-Martinez L, Horcajada JP, Oliver A.
    Antimicrob Agents Chemother; 2017 Nov 14; 61(11):. PubMed ID: 28874376
    [Abstract] [Full Text] [Related]

  • 8. AmpG inactivation restores susceptibility of pan-beta-lactam-resistant Pseudomonas aeruginosa clinical strains.
    Zamorano L, Reeve TM, Juan C, Moyá B, Cabot G, Vocadlo DJ, Mark BL, Oliver A.
    Antimicrob Agents Chemother; 2011 May 14; 55(5):1990-6. PubMed ID: 21357303
    [Abstract] [Full Text] [Related]

  • 9. Role of Pseudomonas aeruginosa low-molecular-mass penicillin-binding proteins in AmpC expression, β-lactam resistance, and peptidoglycan structure.
    Ropy A, Cabot G, Sánchez-Diener I, Aguilera C, Moya B, Ayala JA, Oliver A.
    Antimicrob Agents Chemother; 2015 Jul 14; 59(7):3925-34. PubMed ID: 25896695
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
    Cabot G, Bruchmann S, Mulet X, Zamorano L, Moyà B, Juan C, Haussler S, Oliver A.
    Antimicrob Agents Chemother; 2014 Jun 14; 58(6):3091-9. PubMed ID: 24637685
    [Abstract] [Full Text] [Related]

  • 12. Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients.
    Zamudio R, Hijazi K, Joshi C, Aitken E, Oggioni MR, Gould IM.
    Int J Antimicrob Agents; 2019 Jun 14; 53(6):774-780. PubMed ID: 30831233
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Antimicrobial Effects of β-Lactams on Imipenem-Resistant Ceftazidime-Susceptible Pseudomonas aeruginosa.
    Wi YM, Choi JY, Lee JY, Kang CI, Chung DR, Peck KR, Song JH, Ko KS.
    Antimicrob Agents Chemother; 2017 Jun 14; 61(6):. PubMed ID: 28373200
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Simultaneous and divergent evolution of resistance to cephalosporin/β-lactamase inhibitor combinations and imipenem/relebactam following ceftazidime/avibactam treatment of MDR Pseudomonas aeruginosa infections.
    Alonso-García I, Vázquez-Ucha JC, Lasarte-Monterrubio C, González-Mayo E, Lada-Salvador P, Vela-Fernández R, Aja-Macaya P, Guijarro-Sánchez P, Rumbo-Feal S, Muíño-Andrade M, Fernández-González A, Martínez-Guitián M, Beceiro A, Rodríguez-Iglesias M, Oliver A, Arca-Suárez J, Galán-Sánchez F, Bou G.
    J Antimicrob Chemother; 2023 May 03; 78(5):1195-1200. PubMed ID: 36918743
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pseudomonas aeruginosa carbapenem resistance mechanisms in Spain: impact on the activity of imipenem, meropenem and doripenem.
    Riera E, Cabot G, Mulet X, García-Castillo M, del Campo R, Juan C, Cantón R, Oliver A.
    J Antimicrob Chemother; 2011 Sep 03; 66(9):2022-7. PubMed ID: 21653605
    [Abstract] [Full Text] [Related]

  • 19. Mechanisms leading to in vivo ceftolozane/tazobactam resistance development during the treatment of infections caused by MDR Pseudomonas aeruginosa.
    Fraile-Ribot PA, Cabot G, Mulet X, Periañez L, Martín-Pena ML, Juan C, Pérez JL, Oliver A.
    J Antimicrob Chemother; 2018 Mar 01; 73(3):658-663. PubMed ID: 29149337
    [Abstract] [Full Text] [Related]

  • 20. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM, Hindler JA, Wong-Beringer A, Miller SA.
    Antimicrob Agents Chemother; 2017 Dec 01; 61(12):. PubMed ID: 28993338
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.